Safety of unconventional antibody-drug conjugate L-DOS47 in a phase I/II monotherapy study targeting advanced NSCLC

Authors

Institutions

Publication Details

Journal
Frontiers in Oncology
Published
2025-08-11
DOI
https://doi.org/10.3389/fonc.2025.1544967
Citations
1
Primary Topic
Cancer, Hypoxia, and Metabolism
Type
article
Field-Weighted Citation Impact
0.94
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Safety of unconventional antibody-drug conjugate L-DOS47 in a phase I/II monotherapy study targeting advanced NSCLC

Rodryg Ramlau, Gabrielle M. Siegers, Kazimierz Roszkowski‐Śliż, Cezary Szczylik et al.
1 citations
Frontiers in Oncology
Cancer, Hypoxia, and Metabolism
0.94
article

Safety of unconventional antibody-drug conjugate L-DOS47 in a phase I/II monotherapy study targeting advanced NSCLC

Rodryg Ramlau, Gabrielle M. Siegers, Kazimierz Roszkowski‐Śliż, Cezary Szczylik, Dariusz M. Kowalski, Young Ou, Kim Gaspar, Martin Köbel, Brenda Lee, Aleksandra Szczęsna
article en
1 citations

Abstract

No abstract available for this paper.
Frontiers in OncologyVol. 15
University of Calgary (CA), Masih Daneshvari Hospital (IR), Calgary Laboratory Services (CA), National Centre for Nuclear Research (PL), Helix Biopharma (Canada) (CA), Centrum Leczenia Oparzeń (PL), Instytut Technik Telekomunikacyjnych i Informatycznych (Poland) (PL), National Center for Tuberculosis and Lung Disease (GE), National Institute of Oncology (HU), The Maria Sklodowska-Curie National Research Institute of Oncology (PL)
Good health and well-being
Openalex Percentile: Top 21%
Cancer, Hypoxia, and Metabolism
0.94
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Safety of unconventional antibody-drug conjugate L-DOS47 in a phase I/II monotherapy study targeting advanced NSCLC — Rodryg Ramlau, Gabrielle M. Siegers, et al. · Frontiers in Oncology (2025) | TGRS Research Map | TGRS